WASHINGTON — Federal health officials said Wednesday a long-delayed vaccine from GlaxoSmithKline successfully blocks the leading virus that causes cervical cancer in women.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The Food and Drug Administration's vaccine panel voted overwhelmingly that the vaccine Cervarix appears safe and effective for girls and women ages 10 to 25.
If the FDA follows the group's advice, Glaxo would begin competing against Merck's vaccine Gardasil, which has controlled the U.S. market since 2006.
London-based drugmaker Glaxo already has won approval for its vaccine in Europe, but its U.S. launch was delayed in 2007 when the FDA said it needed more data about the vaccine.
Panelists say newer studies suggest the vaccine is safe, but they recommend follow-up studies to monitor miscarriages and inflammatory-muscular problems reported by a small number of patients.
The group said it was unlikely those problems were related to the vaccine, but said the issues should still be noted on the product labeling.
"This wasn't a pregnancy trial and it wasn't meant to be used in pregnancy, it just happened accidentally," said Dr. Kenneth Noller, of Tufts University. "I think this could be marketed with the usual caveat that it's not to be used in pregnancy."
HPV infects 6 million a year in U.S.
The human papilloma virus, or HPV, infects about 6 million people in the U.S. each year, and is mainly spread through sexual contact. It usually doesn't carry any symptoms and goes away within two years, but rare cases can develop into warts and cancers in both men and women.
Last year, nearly 4,000 women died of cervical cancer in the U.S., less than 1 percent of all cancer-related deaths.
Even if the FDA grants approval, Glaxo will face an uphill battle against Merck's Gardasil, which has had the U.S. market to itself for the last three years. Besides an established brand, Gardasil also boasts an extra degree of protection against sexually transmitted diseases.
Gardasil and Cervarix both defend against HPV strains 16 and 18, which cause about 70 percent of cervical cancer cases. But Merck's vaccine also defends against two other HPV types that cause 90 percent of genital warts, something Cervarix does not target.
Even as the British drugmaker moves closer to competing in the U.S., Whitehouse Station, N.J.-based Merck is seeking approval to begin marketing Gardasil to boys and men.
The panel is scheduled to vote later Wednesday on Gardasil as a preventive measure against genital warts in males.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.